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S U M M A R Y
Objectives: We aimed to determine the rate of breakthrough varicella in Turkey, a country with low
varicella vaccination coverage.
Methods: This study was conducted between April 2008 and March 2009 at the Well-Child Clinic at Ege
University and pediatricians’ ofﬁces. We collected information on vaccination status and varicella
infection using a questionnaire. In order to elicit more details about the severity of illness, we
interviewed all parents and reviewed the clinician records. Vaccination status was veriﬁed from the
medical records or vaccination cards with dates.
Results: A total of 2802 children were evaluated. Of these, 1683 had been vaccinated with a single dose of
varicella vaccine and 1119 were unvaccinated. Among vaccinated children, 466 (27.7%) had
breakthrough varicella. Vaccinated children tended to have mild varicella. However, about 25% of
breakthrough cases had moderate or severe disease. Children who were vaccinated 5 years previously
had a 3.7-fold higher risk of breakthrough disease than those who were vaccinated <5 years before.
Vaccination at younger than 15 months of age was not signiﬁcantly associated with an increased risk of
breakthrough infection.
Conclusions: Breakthrough varicella is not rare in Turkey where varicella infections are common. A
longer interval since vaccination may be a risk factor for developing breakthrough varicella. Children
who had been vaccinated >5 years previously were at risk for breakthrough disease. A two-dose varicella
vaccine policy may be needed to provide improved protection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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A live attenuated varicella vaccine (Oka strain) was developed
in the early 1970 s.1,2 However, routine varicella vaccination
programs targeting healthy children have only been implemented
in a relatively small number of countries.3–7 After the implemen-
tation of one-dose varicella vaccination, varicella-related morbid-
ity and mortality have dramatically decreased in these
countries.2,8–11 Despite this decline, some studies have reported
that varicella outbreaks continue to occur in day-care centers and
schools.12–15
There have been numerous questions about the effectiveness of
varicella vaccine.16 Most studies have shown that the efﬁcacy of
one-dose vaccination is about 80–85% against varicella disease of
any severity.3,15,17–20 However, some studies have reported a
vaccine effectiveness as low as 20–56% against disease during
varicella outbreaks in day-care centers.12,21,22 Serological studies* Corresponding author. Tel.: +90 232 3901020; fax: +90 232 4621213.
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doi:10.1016/j.ijid.2011.03.016have also shown that about 15–24% of children receiving one dose
of varicella vaccine do not have protective levels of antibody.23,24
Thus, approximately 15–20% of vaccinated children may develop
breakthrough varicella disease.25
A routine varicella vaccination program has not yet been
implemented in Turkey. However, two live attenuated varicella
virus vaccines (Varilrix, GlaxoSmithKline and Okavax, Sanoﬁ-
Pasteur) have been available since mid-1999 and a single dose of
the vaccine is administered by some physicians in their private
practice to healthy children aged 12 months to 12 years. According
to vaccine sales ﬁgures, it is estimated that only 15–20% of Turkish
children have been immunized with varicella vaccine for more
than a decade. Therefore, frequent outbreaks of varicella are seen
in our country. Moreover, an outbreak of varicella among
vaccinated schoolchildren has also been reported from Turkey.26
To our knowledge, the rate of breakthrough varicella is unclear
in Turkey, where varicella vaccination rates are low and primary
varicella infections are common. The aim of the present study was
to determine varicella rates in healthy unvaccinated and one-dose
vaccinated Turkish children and to assess the performance of a
one-dose varicella vaccine, because this may be important forses. Published by Elsevier Ltd. All rights reserved.
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the potential risk factors for breakthrough disease, such as time
since vaccination, younger age at vaccination, and a history of
asthma or eczema.
2. Methods
This study was carried out at the Well-Child Clinic at Ege
University Medical School and in the private pediatricians’ ofﬁces
in Izmir, Turkey, between April 1, 2008 and March 31, 2009. All
healthy children aged >2 years who had been seen for routine
well-child visits during this study period and who had regular
clinical records were enrolled in the study. Children without
medical records and those with an immune deﬁciency or chronic
disease history, such as oncogenic diseases, chronic liver and renal
diseases and rheumatologic diseases, were not included. We
interviewed the parents and they also ﬁlled in a questionnaire
about their child’s demographic characteristics, past varicella
infection and the severity of illness, medical and vaccination
history, and history of conditions including asthma and eczema.
Varicella history and the severity of illness were determined by
interviews with the parents. The medical records of all children
were reviewed to obtain information about previous vaccination
status, health conditions and detailed information about varicella
infection. The children with medical records who were no longer
being seen in these practices were not included in our study
because it was not possible to carry out the interview with their
parents and obtain (and verify) more information about the
children and their disease history.
The date of varicella vaccination was veriﬁed from the
clinicians’ vaccination records and the children’s vaccine cards.
After a review of the medical records, children of the families who
did not accept participation at any stage of the study, the children
with an uncertain vaccination date or suspicious varicella illness
history, and those who had received two doses of varicella vaccine
were excluded from the study.
Breakthrough varicella was considered as varicella in a child
who had been vaccinated more than 42 days before the onset of
rash. Since the varicella vaccine may cause rash, we excluded
children with varicella who had been vaccinated within the
previous 42 days. Illness was classiﬁed as mild (fewer than 50
lesions, duration of fever 3 days, and duration of disease 4 days
without complications) or moderate–severe (generalized lesions,Interview  with p ar
Chil dren who  had med ical records  available 
n = 3082  (77.5%) 
Excl uded cases, n = 280 (9.1%)  
• The family does not  accept, n = 78  
(2.5%)  
• Ha ve a medical record,  but 
insufficient  data (suspicious 
varicella history and uncertain 
vacci nati on time), n = 188 (6.1%)  
• Children vaccinated with two 
doses before study on set , n = 14 
(0.5%)  
Chil dren  eligible for th
n = 2802 (90.9%
Vaccinated  
n = 1683 (60.1%) 
Figure 1. Study design and selduration of fever longer than 4 days, disease duration longer than 5
days or the occurrence of any complications or hospitalization).
For the calculation of the incidence rates of breakthrough
varicella, we used person-time analysis for vaccinated and
unvaccinated children. For unvaccinated children, time 0 was
deﬁned as 12 months of age, and the end-point for time at risk was
either the occurrence of varicella or the date of the survey. For
vaccinated children, time 0 was deﬁned as the date they received
the varicella vaccine, and the end-point for time at risk was either
the occurrence of breakthrough varicella or the date of the survey.
Varicella vaccine effectiveness was determined by the cohort
method.27,28 Vaccine effectiveness (VE) was calculated using the
equation: VE% = [(ARU  ARV)/ARU]  100. ARU, the attack rate in
the unvaccinated, is equal to the number of cases in unvaccinated
children divided by the total person-time of observation in
unvaccinated children. ARV, the attack rate in the vaccinated, is
equal to the number of cases in vaccinated children divided by the
total person-time of observation in vaccinated children. The
effectiveness of the varicella vaccine was determined for any form
of varicella as well as for moderate to severe varicella.
Statistical analysis was performed with SPSS for Windows
(version 15.0) and Open-Epi (version II). The differences in
characteristics between vaccinated and unvaccinated children
were assessed using the t-test for continuous variables and the Chi-
square test for categorical variables. To determine the independent
potential risk factors for breakthrough disease among vaccinated
children, the logistic regression model was used. A p-value of <0.05
was considered signiﬁcant.
3. Results
For this study, a total of 3976 families were interviewed.
Children without medical records or with an immune deﬁciency
or chronic disease history were not included in the study. A total
of 3082 (77.5%) children who had regular medical records were
enrolled in the study. Of these, 280 (9.1%) were excluded: 78
(2.5%) parents refused to participate in the study, the data were
insufﬁcient for 188 (6.1%) children, and 14 children had been
vaccinated with a second dose of varicella vaccine. Thus, 2802
(90.9%) of the eligible children were included in the study
(Figure 1).
Characteristics of these children are presented in Table 1. Of the
2802 children, 1683 (60.1%) had been vaccinated with a single doseents  n  = 3976  
Excl uded cases, n = 894 (22.5%)  
• No previous medical records, n = 670 
(16 .9%)  
• Chronic  diseases, n = 224 (5.6%)  (imm une 
deficiency, children with  oncogenic 
diseases, renal  fai lure, chronic li ver diseases) e  study  
) 
Unvaccinated  
n = 1119 (39. 9%) 
ection of eligible children.
Table 1
Characteristics of eligible vaccinated and unvaccinated children
Vaccinated children (n = 1683) Unvaccinated children (n = 1119) p-Value
Age, months
Median 93 95 0.13
Range 24–186 24–185
Gender, n (%)
Female 822 (48.8) 600 (53.6) 0.11
Male 861 (51.2) 519 (46.4)
Varicella history, n (%)
Yes 466 (27.7) 723 (64.6) <0.001
No 1217 (72.3) 396 (35.4)
Person who made the diagnosis, n (%)
Physician 413 (88.6) 643 (88.9) 0.84
Health-care providers 15 (3.2) 16 (2.2)
Family 38 (8.2) 64 (8.9)
Severity of illness, n (%)
Mild 351 (75.3) 436 (60.3) <0.001
Moderate/severe 115 (24.7) 287 (39.7)
Table 2
Varicella incidence rates in vaccinated and unvaccinated children
Vaccinated children (n = 1683) Unvaccinated children (n = 1119)
No. of varicella cases 466 723
Person-years 10 228 6013
Varicella incidence (cases/1000 person-years) 45.5 (41.5–48.9)a 120.2 (111.6–129.3)a
Vaccine effectiveness 62.1 (57.4–66.3)a
a The values in parenthesis are 95% conﬁdence intervals.
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vaccinated and unvaccinated groups of children were similar in
terms of age and gender distribution. Overall, 1189 of 2802 (42.4%)
had a history of varicella. The varicella history of all children was
obtained from the parents. About 92% of varicella cases were
diagnosed by a physician or a health care provider. Among 1683
vaccinated children, 466 (27.7%) had a history of breakthrough
varicella, whereas 723 (64.6%) of 1119 unvaccinated children had a
natural varicella history.
During the study period, there was a total of 16 241 person-
years; 63.0% (10 228 person-years) of the total person-time was
vaccinated person-time and 37.0% (6013 person-years) was
unvaccinated person-time. Table 2 shows the varicella incidence
rates by vaccination status. The overall varicella incidence rate in
the vaccinated group was signiﬁcantly lower than that in the
unvaccinated group (VE = 62.1%, 95% conﬁdence interval (CI) 57.4–
66.3; p < 0.001).
Compared with unvaccinated children, vaccinated children
tended to have a mild varicella infection. However, the disease was
moderate or severe in 24.7% of children with breakthrough
varicella (Table 1). Four children (three with varicella pneumonia
and one with encephalitis) in the unvaccinated group and one child
in the vaccinated group had severe varicella that required
hospitalization. This vaccinated case was 10 years old whenTable 3
Risk factors for breakthrough varicella among vaccinated children
Breakthrough varicella (n = 466), n (%) N
Time since vaccination
<5 years 81 (13.2) 5
5 years 385 (35.9) 6
Age at vaccination
15 months 162 (27.0) 4
<15 months 304 (28.0) 7
Asthma 4 (0.9) 9
Eczema 6 (1.3) 1
OR, odds ratio; CI, conﬁdence interval.admitted to the hospital and was in the ninth year of varicella
vaccination. The child was hospitalized because of disseminated
rash and fever and received oral and topical acyclovir therapy for
conjunctivitis; this case recovered fully. The comparative rates of
hospitalization for unvaccinated and vaccinated varicella cases
were calculated, but there was no statistically signiﬁcant differ-
ence (p > 0.05).
The median age at vaccination was 13 months; the median time
elapsed since vaccination was 72 months. The frequency of
breakthrough varicella among children who had been vaccinated
5 years previously was signiﬁcantly higher than in those who had
been vaccinated <5 years previously (35.9% vs. 13.2%, p < 0.001).
The logistic regression model showed that the risk of breakthrough
varicella increased with a longer interval since vaccination.
Children who had been vaccinated 5 years previously had a
3.7-fold higher risk of breakthrough disease than children who had
been vaccinated <5 years before (odds ratio (OR) 3.7, 95% CI 2.82–
4.79; p < 0.001) (Table 3). Vaccination at younger than 15 months
of age was not signiﬁcantly associated with an increased risk of
breakthrough infection, as compared to vaccination at older ages
(15 months) (OR 1.05, 95% CI 0.84–1.32; p = 0.66). Asthma and
eczema were not identiﬁed as risk factors for breakthrough
disease. All immunized children had been vaccinated with
varicella vaccine at least 4 weeks after measles–mumps–rubellao illness (n = 1217), n (%) OR (95% CI) p-Value
31 (86.8)
86 (64.1) 3.7 (2.82–4.79) <0.001
37 (73.0)
80 (72.0) 1.05 (0.84–1.32) 0.66
 (0.7) 1.4 (0.52–3.88) 0.59
1 (0.9) 1.2 (0.35–3.79) 0.76
Figure 2. Rates of breakthrough varicella among vaccinated children by the year after vaccination.
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administered on the same day.
The cumulative rate of breakthrough varicella increased
signiﬁcantly with each year after vaccination, from 3.1% (95% CI
2–11.3%) within the ﬁrst year to 18.8% (95% CI 13.8–24.1%) at 5
years and 29.6% (95% CI 23.4–35.3%) at 8 years (Figure 2). The rate
of breakthrough varicella was 63.0% (95% CI 45.6–59.0%) for 10
years after vaccination. The person-years of the vaccinated group
was more than that of the unvaccinated group. Hence, the
vaccinated children had potentially many more months of possible
exposure.
4. Discussion
This study indicates that the breakthrough varicella rate is
27.7% in healthy children immunized with a single dose of varicella
vaccine in our region. This rate is similar to the rates (10–34%)
reported in most of the previous studies of breakthrough
varicella.3,29,30 In Turkey, the incidence of varicella infections is
unclear since it is not an obligatory reported disease, and there
have not been enough seroepidemiological studies on this
subject.31 In 2002, a study by Kanra et al. and other
seroepidemiological studies in the later period indicated that
varicella infections are mostly seen in primary school children.32 In
our country, the varicella vaccine is not widely used and wild
varicella infection is prevalent. So, it is likely that most of the
vaccinated children are exposed to wild-type varicella virus.
Vaccination coverage in the private sector is high, and families
have to pay for the varicella vaccine. Because we chose a study
population from the private sector and well-child clinics of the
universities, vaccination coverage appears to be high as compared
to the general population.
As the immunity of the children is boosted by subclinical
infection through this natural exposure, breakthrough varicella
may develop in some vaccinated children after exposure to
someone with an infectious case. Although most cases of
breakthrough varicella are mild, the patients can be contagiousfor unvaccinated persons.10,12,14,17 It is reported that breakthrough
varicella cases are one-third to half as infectious as unvaccinated
cases.33 The breakthrough infections may also be more severe than
previously thought; about a quarter of breakthrough varicella
cases developed moderate or severe disease in this study.
Moreover, one breakthrough case was severe enough to warrant
hospitalization. In contrast to most of the previous studies, our
ﬁndings are in accordance with the study by Chaves et al. in this
respect.34 In a recent publication, it was also reported that the
mean duration of rash in breakthrough varicella and non-
vaccinated cases did not differ signiﬁcantly.35
An increased risk of breakthrough disease may also be
associated with time since vaccination, younger age at vaccination,
a history of asthma or eczema, and vaccination with varicella
vaccine within 30 days of live attenuated MMR vac-
cine.1,10,12,13,21,25,36,37 However, these associations were not
consistently reproduced in all studies.1,14,25,38 A small study
suggested that asthmatics have a seven-fold increased risk of
breakthrough varicella.39 On the other hand, two large studies in
children found no association between asthma and the risk of
breakthrough varicella.13,37 Similarly, no correlation between
breakthrough varicella and asthma/eczema was found in our
study. No children had been vaccinated with varicella vaccine at
least 4 weeks after MMR vaccination.
Several studies have suggested that vaccination in children
younger than 15 months of age is a risk factor for breakthrough
varicella.13,37,38,40,41 However, there are studies indicating that
early age at vaccination is not a risk factor for breakthrough
infection.15,25 Two recent prospective cohort studies found no
increased risk for breakthrough disease among children who were
vaccinated at age 12–14 months compared with 15–23
months.42,43 In this study, we found no association between
young age at vaccination (<15 months of age) and breakthrough
varicella.
We observed that the frequency of breakthrough disease among
vaccinated children increased with the time since vaccination.
Children who had been vaccinated more than 5 years previously
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had been vaccinated less than 5 years before. Va´zquez et al.41
found vaccine effectiveness to be stable during the second through
eighth years after vaccination. In contrast, our study indicates that
the rate of breakthrough varicella increased signiﬁcantly with each
year after vaccination, from 3.1% within the ﬁrst year to 29.6% at 8
years. Furthermore, the breakthrough rate reached 63.0% at 10
years. Similarly, Chaves et al.25 suggested that incidence rates of
breakthrough varicella increased more than 12 times from the ﬁrst
year of vaccination to the eighth year after vaccination. Other
studies have also demonstrated that the risk of breakthrough
infection increases over time.12,13,33,38,44 This is presumably a
result of waning immunity in some vaccinated children.
Some studies have reported that reduced circulation of varicella
zoster virus (VZV) in the study area or an inadequate initial
response to vaccination may have contributed to the waning
vaccine-induced immunity to varicella.25,45,46 According to vaccine
sales ﬁgures, it is estimated that only 15–20% of Turkish children
have been immunized with varicella vaccine. Although epidemio-
logical data are not available for our country, the circulation of VZV
in Turkey appears not to have decreased yet and frequent
outbreaks of varicella are seen in our country.26 Hence, waning
vaccine-induced immunity to varicella may be the explanation, but
it may not be the sole explanation.
The present study had some limitations. Our study was
observational (cross-sectional) and not a cohort study. In a
cross-sectional study, there is no ability to control for a ‘cohort’
effect of differing exposures over time. Parental reporting and
clinician records were accepted as valid; serologic evidence of
immunity or susceptibility was not investigated. This method
might have resulted in an overestimation or underestimation of
the rates of breakthrough disease; however, physicians diagnosed
the majority of cases. Subtle presentations of breakthrough disease
that were not clinically recognized could have led to an
underestimation of breakthrough rates. On the other hand, some
unexplained rashes misclassiﬁed as breakthrough disease (such as
enteroviral infections or insect bites) could have led to an
overestimation of the rates of breakthrough disease. Finally, some
parents had difﬁculty remembering the number of lesions and the
duration of illness. However, clinician records were also used to
validate parental information and health care providers were
contacted to verify any history of varicella.
In conclusion, our study indicates that breakthrough varicella is
frequent in an environment in which primary varicella infections
are common. In June 2006, the Advisory Committee on Immuni-
zation Practices recommended a routine two-dose schedule for
varicella vaccination, to improve vaccine-induced immunity and
the control of varicella and to minimize the burden of break-
through varicella disease.47 A two-dose schedule for varicella
vaccination also seems to be suitable for our children. However,
after the implementation of a two-dose vaccination schedule, it is
important to monitor changes in varicella epidemiology with a
focus on varicella disease among vaccinated children.
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to this article to disclose.
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